Mackenzie Financial Corp Acquires 10,026 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mackenzie Financial Corp raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 74.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,439 shares of the biotechnology company’s stock after buying an additional 10,026 shares during the period. Mackenzie Financial Corp’s holdings in BioCryst Pharmaceuticals were worth $140,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares during the period. Teacher Retirement System of Texas increased its stake in shares of BioCryst Pharmaceuticals by 4.9% during the third quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 2,519 shares during the period. Fifth Third Bancorp increased its stake in shares of BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,500 shares during the period. Teza Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 12.8% during the third quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 4,180 shares during the period. Finally, Great Valley Advisor Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 34.7% during the third quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 4,200 shares during the period. Institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $13.83.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $4.27 on Tuesday. The company has a market capitalization of $881.03 million, a P/E ratio of -3.55 and a beta of 1.90. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $9.06. The business’s 50 day simple moving average is $5.07 and its 200 day simple moving average is $5.52.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.